These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 9533481

  • 1. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
    Danelon G, Mascaretti O, Radice M, Power P, Calcagno ML, Mata EG, Gutkind G.
    J Antimicrob Chemother; 1998 Feb; 41(2):313-5. PubMed ID: 9533481
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
    Helfand MS, Bethel CR, Hujer AM, Hujer KM, Anderson VE, Bonomo RA.
    J Biol Chem; 2003 Dec 26; 278(52):52724-9. PubMed ID: 14534312
    [Abstract] [Full Text] [Related]

  • 10. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA, Rudin SA, Shlaes DM.
    FEMS Microbiol Lett; 1997 Mar 01; 148(1):59-62. PubMed ID: 9066111
    [Abstract] [Full Text] [Related]

  • 11. Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.
    Hedberg M, Lindqvist L, Tunér K, Nord CE.
    J Antimicrob Chemother; 1992 Jul 01; 30(1):17-25. PubMed ID: 1331018
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
    Hedberg M, Lindqvist L, Tunér K, Nord CE.
    Eur J Clin Microbiol Infect Dis; 1992 Nov 01; 11(11):1100-4. PubMed ID: 1338315
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
    Tajada P, Gomez-Graces JL, Alós JI, Balas D, Cogollos R.
    Antimicrob Agents Chemother; 1996 Aug 01; 40(8):1924-5. PubMed ID: 8843305
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb 01; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.